4Life Transfer Factor - "Kesihatan Imunisasi"

1949
Dr H. Sherwood Lawrence, semasa mengkaji penyakit TB (Tuberculosis) telah terjumpa dengan “molikul informasi” yang terkandung di dalam sel darah putih manusia (sistem imun). Beliau dapati molekul tersebut boleh dipindah dari satu orang kepada orang yang lain (dan dapat memberikan penerimanya, “kekebalan” dari penyakit tersebut). Beliau menamakan molekul tersebut “Transfer Factor” (TF). Kajian selanjutnya telah mendapati Transfer Factor juga terkandung di dalam kolostrum (susu awal) dan kuning telur.


1998
Selama 50 tahun setelah penemuan Transfer Factor, para saintis dan para doktor dari lebih dari 60 negara telah menjalankan kajian keatasnya. Lebih daripada 3,500 lapuran kajian saintifik telah di terbitkan dan lebih dari US$40 juta telah dibelanjakan atas kajian2 tersebut. Pada tahun 2002, proses pengekstraksi Transfer Factor dari kolostrum lembu & kuning telur ayam telah di patent oleh 4Life Research .

Bukan!!!!!
Vitamin, Galian, Enzim, Herba, Kolostrum, Dadah, Cell-Food, Steroid, Hormon

Transfer Factors adalah “molekul penghantar maklumat” atau “immune IQ”. Transfer Factors di ekstrak daripada kolostrum (susu awal lembu) dan kuning telor (ayam)

1 biji TF (200mg) berpotensi mengenali lebih dari 100,000 jenis kuman, virus, kulat, parasit, bakteria dsb, serta sel-sel yang “rosak”
Kekuatan 1 biji pil TF sama seperti 75-100 biji pil kolostrum dalam fungsi pembinaan daya imun (peningkatan sel NK)

4Life® Merupakan Syarikat MLM No 1 Dari USA. Kini Baru Dilancarkan Di Malaysia.

REG.NO : 575339-A AJL.NO : 931508

=>4Life® Merupakan Syarikat MLM Pertama Yang Telah Disenaraikan Dalam INC 500

=>Produk 4Life® Yang Unik Tiada Persaingan, Telah Di Patenkan Eksklusif, Tidak Terdapat Dalam Pasaran Dari Syarikat MLM Lain.

=>Transfer Factor™ Adalah 100% ASLI, SUCI & HALAL! Terbukti Selamat Untuk Semua Lapisan Umur Tanpa Sebarang Kesan Sampingan. (Disahkan HALAL oleh IFANCA ) Sila Rujuk www.IFANCA.org

=>MENGHANTAR INFORMASI pada sel2 imun kita untuk dapat mengenali rupa2 virus, bakteria, kuman, parasit, serta sel2 “rosak” seperti fibroid, tumor & sel kanser

=>MERANGSANG sistem imun untuk menyerang musuh2 serta mengingati rupanya agar tindakan dapat diambil dengan lebih cepat pada serangan di masa hadapan

=>MENENANGKAN sistem imun untuk kembali kepada status “standby” apabila musuh2 telah berjaya diatasi.

=>Racun Serangga Tanaman
=>Pencemaran Udara/ Air/ Klorin
=>Asap Rokok/ Asap Kereta
=>Kosmetik/ Produk Dandanan
=>Spray Aerosol/ Alkohol/ Kimia
=>Dadah/ Steroid/ Antibiotik
=>Radiasi/ X-Ray/ Mikrowave
=>Pil Perancang Keluarga
=>Perasa/ Pewarna/ Pengawit
=>Makanan Berproses
=>Habuk/ Hama/ Virus
=>Kuman/ Bakteria/ Parasit
=>Stress/ Tekanan

Kajian Aktiviti Perangsang Sel Imun (NK Sel), Telah Dilakukan Oleh Institue of Longevity Medicine, California USA, Selama 7 Tahun (1992 - 1999) ke atas 198 produk-produk terkenal, antaranya adalah:

Menunjukan bahawa...
900% Lebih baik dari Herba dan Nutrien yang dikaji oleh Ahli Saintis dalam fungsi merangsang dan meningkatkan daya imun

hasil kajian yang telah dikeluarkan oleh JANA (Journal of American Nutraceutical Association)

1. TRANSFER FACTOR ADV PLUS™ … 437%
2. TRANSFER FACTOR ADV™ ……….…. 283%

3. IP-6 ………………………………………….….…...49%
4. PLANT POLYSACCHARIDES ….…….….. 48%
5. ECHINACEA ……………………….............. 43%
6. SHITAKE MUSHROOM ………………….….. 42%
7. CORDYCEPS FORMULA………………….... 28%
8. BOVINE COLOSTRUM ..................... 23%
9. PHYTONUTRIENT FORMULA …………….. 21%
10. ENDOCRINE FORMULA ………………….….. 16%
11. ALOE VERA (Acemannan) ………………... 15%
12. NONI (Morinda Citrafolia) …….…….……..15%

Transfer Factor adalah..
30 kali ganda lebih berkesan dari royal jelly, spirulina, ginseng,
propolis, green tea, wheat grass & ginkgo
29 kali ganda lebih berkesan dari noni & aloe vera
19 kali ganda lebih berkesan dari kolostrum(susu awal lembu)
15 kali ganda lebih berkesan dari cordyceps
10 kali ganda lebih berkesan dari echinaccea & shiitake
9 kali ganda lebih berkesan dari lingzhi, IP-6 & ganoderma

Rev Alerg Mex. 2007 Jul-Aug;54(4):134-9.
Indications, usage, and dosage of the transfer factor.
Berrón-Pérez R, Chávez-Sánchez R, Estrada-García I, Espinosa-Padilla S, Cortez-Gómez R, Serrano-Miranda E, Ondarza-Aguilera R, Pérez-Tapia M, Pineda Olvera B, Jiménez-Martínez Mdel C, Portugués A, Rodríguez A, Cano L, Pacheco PU, Barrientos J, Chacón R, Serafín J, Mendez P, Monges A, Cervantes E, Estrada-Parra S.
Servicio de Inmunología, Instituto Nacional de Pediatría, S.S.

The transfer factor (TF) was described in 1955 by S. Lawrence. In 1992 Kirkpatrick characterized the specific TF at molecular level. The TF is constituted by a group of numerous molecules, of low molecular weight, from 1.0 to 6.0 kDa. The 5 kDa fraction corresponds to the TF specific to antigens. There are a number of publications about the clinical indications of the TF for diverse diseases, in particular those where the cellular immune response is compromised or in those where there is a deficient regulation of the immune response. In this article we present our clinical and basic experiences, especially regarding the indications, usage and dosage of the TF. Our group demonstrated that the TF increases the expression of IFN-gamma and RANTES, while decreases the expression of osteopontine. Using animal models we have worked with M. tuberculosis, and with a model of glioma with good therapeutic results. In the clinical setting we have worked with herpes zoster, herpes simplex type I, herpetic keratitis, atopic dermatitis, osteosarcoma, tuberculosis, asthma, post-herpetic neuritis, anergic coccidioidomycosis, leishmaniasis, toxoplasmosis, mucocutaneous candidiasis, pediatric infections produced by diverse pathogen germs, sinusitis, pharyngitis, and otits media. All of these diseases were studied through protocols which main goals were to study the therapeutic effects of the TF, and to establish in a systematic way diverse dosage schema and time for treatment to guide the prescription of the TF.
PMID: 18297853 [PubMed - in process]

Biotherapy. 1996;9(1-3):109-15.
Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study.
Prasad U, bin Jalaludin MA, Rajadurai P, Pizza G, De Vinci C, Viza D, Levine PH.
University of Malaya, Kuala Lumpur, Malaysia.

Overall survival of nasopharyngeal carcinoma (NPC) at UICC stage IV still remains unsatisfactory even with combination chemotherapy (CT) and radio-therapy (RT). In view of the association of reactivation of Epstein-Barr virus (EBV) with the development and recurrence of NPC, immunotherapy in the form of transfer factor (TF) with specific activity against EBV (TF-B1) was suggested as an adjuvant to a combination of CT and RT in order to improve survival. In the present study, 6 UICC stage IV patients received TF-B1 and another 6 patients matched for disease stage were given TF prepared from peripheral blood leucocytes (TF-PBL). Results were compared with another 18 patients matched by age, sex, and stage of disease who received standard therapy without TF during the same period (C group). After a median follow up of 47.5 months, the survival for the TF-B1 group was found to be significantly better (P = < 0.05) than the PBL and C group. While the 8 patients with distant metastasis (DM), not treated with TF-B1 (6 in the control and 2 in the PBL group), died due to progressive disease (average survival being 14.3 months), both patients with DM in the TF-B1 group had complete remission: one died of tuberculosis after surviving for 3.5 years and another is still alive, disease free, after 4.2 years. Although the series involved a small number of cases, the apparent effect of adjuvant immunotherapy in the form of TF with anti-EBV activity is of considerable interest.

PMID: 8993768 [PubMed - indexed for MEDLINE]

Biotherapy. 1996;9(1-3):133-8.
Use of transfer factor for the treatment of recurrent non-bacterial female cystitis (NBRC): a preliminary report.
De Vinci C, Pizza G, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V, Viza D.
Immunodiagnosis and Immunotherapy Unit, 1st-Division of Urology, Bologna, Italy.

Results of conventional treatment of female non-bacterial recurrent cystitis (NBRC) are discouraging. Most patients show an unexpected high incidence of vaginal candidiasis, while their cell mediated immunity to Herpes simplex viruses (HSV) and Candida antigens seems impaired, and it is known that the persistence of mucocutaneous chronic candidiasis is mainly due to a selective defect of CMI to Candida antigens. Twenty nine women suffering of NBRC, and in whom previous treatment with antibiotics and non-steroid anti-inflammatory drugs was unsuccessful, underwent oral transfer factor (TF) therapy. TF specific to Candida and/or to HSV was administered bi-weekly for the first 2 weeks, and then once a week for the following 6 months. No side effects were observed during treatment. The total observation period of our cohort was 24379 days with 353 episodes of cystitis recorded and a cumulative relapse index (RI) of 43. The observation period during and after treatment was 13920 days with 108 relapses and a cumulative RI of 23 (P < 0.0001). It, thus, seems that specific TF may be capable of controlling NBRC and alleviate the symptoms.
PMID: 8993771 [PubMed - indexed for MEDLINE]